(0.24%) 5 144.00 points
(0.13%) 38 491 points
(0.39%) 17 916 points
(-0.92%) $83.08
(0.73%) $1.937
(-0.07%) $2 345.50
(0.04%) $27.55
(2.21%) $942.50
(-0.16%) $0.933
(-0.11%) $11.01
(-0.32%) $0.798
(1.31%) $93.08
Live Chart Being Loaded With Signals
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally...
Stats | |
---|---|
今日成交量 | 26 688.00 |
平均成交量 | 43 979.00 |
市值 | 1.59B |
EPS | $0 ( 2024-01-25 ) |
下一个收益日期 | ( $0.310 ) 2024-05-28 |
Last Dividend | $12.81 ( 2018-12-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.75 |
ATR14 | $0.0200 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Sell | 712 500 | Warrant (right to buy) |
2010-11-04 | Sun Pharmaceutical Industries Ltd | Buy | 5 159 765 | Ordinary Shares |
2010-11-01 | Franklin Resources Inc | Sell | 5 159 765 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 84 transactions |
Buy: 16 575 249 | Sell: 25 681 902 |
音量 相关性
Taro Pharmaceutical 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Taro Pharmaceutical 相关性 - 货币/商品
Taro Pharmaceutical 财务报表
Annual | 2023 |
营收: | $572.95M |
毛利润: | $268.32M (46.83 %) |
EPS: | $0.680 |
FY | 2023 |
营收: | $572.95M |
毛利润: | $268.32M (46.83 %) |
EPS: | $0.680 |
FY | 2022 |
营收: | $561.35M |
毛利润: | $293.12M (52.22 %) |
EPS: | $1.550 |
FY | 2021 |
营收: | $548.97M |
毛利润: | $296.66M (54.04 %) |
EPS: | $-10.12 |
Financial Reports:
No articles found.
Taro Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.81 | 2018-12-10 |
Last Dividend | $12.81 | 2018-12-10 |
Next Dividend | $0 | N/A |
Payout Date | 2018-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.22 | -- |
Div. Sustainability Score | 5.86 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 4.03 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $12.81 | 12.40% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0748 | 1.500 | 8.50 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0211 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0261 | 1.500 | -0.821 | -1.231 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.022 | 1.500 | 5.43 | 8.15 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.55 | 1.000 | -2.05 | -2.05 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 8.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.480 | 1.000 | 5.33 | 5.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0360 | 1.000 | -1.280 | -1.280 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.282 | 0.800 | -1.451 | -1.161 | [0.5 - 2] |
Total Score | 5.86 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.87 | 1.000 | 6.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0261 | 2.50 | -0.528 | -1.231 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 9.24 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.769 | 1.500 | -8.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.65 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Taro Pharmaceutical
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。